Paper40407337
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity.
Jia Y and 9 others. Antimicrob Agents Chemother, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity. Papers, record 40407337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40407337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mycobacterium abscessus | Major topic |
| Anti-Bacterial Agents | Major topic |
| Mycobacterium Infections, Nontuberculous | Major topic |
| Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) | Major topic |
| Animals | |
| Microbial Sensitivity Tests | |
| Mice | |
| Macrophages | |
| Humans | |
| Female |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81672063 | National Natural Science Foundation of China | PubMed | ||
| 81971973 | National Natural Science Foundation of China | PubMed | ||
| 82270005 | National Natural Science Foundation of China | PubMed | ||
| 81800003 | National Natural Science Foundation of China | PubMed | ||
| 22ZR1452000 | Natural Science Foundation of Shanghai Municipality | PubMed | ||
| 23S11901400 | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission | PubMed | ||
| 20244Z0017 | Shanghai Municipal Health Commission Excellence Project | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35969055 | A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35969055 | PubMed |
| 2 | 25568071 | Direct inhibitors of InhA are active against Mycobacterium tuberculosis. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/25568071 | PubMed |
| 3 | 22290346 | Mycobacterium abscessus: a new antibiotic nightmare. | J Antimicrob Chemother | 2012 | https://conductscience.org/library/papers/22290346 | PubMed |
| 4 | 8284673 | inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. | Science | 1994 | https://conductscience.org/library/papers/8284673 | PubMed |
| 5 | 31507579 | Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease. | Front Microbiol | 2019 | https://conductscience.org/library/papers/31507579 | PubMed |
| 6 | 30689764 | Mycobacterium abscessus and Antibiotic Resistance: Same As It Ever Was. | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30689764 | PubMed |
| 7 | 29712658 | Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29712658 | PubMed |
| 8 | 32317266 | KatG as Counterselection Marker for Nontuberculous Mycobacteria. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32317266 | PubMed |
| 9 | 32086501 | Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. | Nat Rev Microbiol | 2020 | https://conductscience.org/library/papers/32086501 | PubMed |
| 10 | 28575382 | In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28575382 | PubMed |
| 11 | 21292749 | Deletion of the mmpL4b gene in the Mycobacterium abscessus glycopeptidolipid biosynthetic pathway results in loss of surface colonization capability, but enhanced ability to replicate in human macrophages and stimulate their innate immune response. | Microbiology (Reading) | 2011 | https://conductscience.org/library/papers/21292749 | PubMed |
| 12 | 29437627 | Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29437627 | PubMed |
| 13 | 30880280 | M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis. | Eur Respir J | 2019 | https://conductscience.org/library/papers/30880280 | PubMed |
| 14 | 26488279 | Assembly of the Mycobacterial Cell Wall. | Annu Rev Microbiol | 2015 | https://conductscience.org/library/papers/26488279 | PubMed |
| 15 | 29277667 | Triclosan and its derivatives as antimycobacterial active agents. | Eur J Pharm Sci | 2018 | https://conductscience.org/library/papers/29277667 | PubMed |
| 16 | 32314749 | Fast chemical force microscopy demonstrates that glycopeptidolipids define nanodomains of varying hydrophobicity on mycobacteria. | Nanoscale Horiz | 2020 | https://conductscience.org/library/papers/32314749 | PubMed |
| 17 | 37314394 | New therapeutic strategies for Mycobacterium abscessus pulmonary diseases - untapping the mycolic acid pathway. | Expert Rev Anti Infect Ther | 2023 | https://conductscience.org/library/papers/37314394 | PubMed |
| 18 | 32636299 | Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. | Eur Respir J | 2020 | https://conductscience.org/library/papers/32636299 | PubMed |
| 19 | 19171799 | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19171799 | PubMed |
| 20 | 24752273 | Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24752273 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41519752 | Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo. | BMC Microbiol | 2026 | https://conductscience.org/library/papers/41519752 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40407337
GET https://conductscience.org/api/papers/v1/40407337/references?page=2